

Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Correction to: *Nature Communications*
<https://doi.org/10.1038/s41467-022-32551-2>,
 published online 22 August 2022

<https://doi.org/10.1038/s41467-023-35835-3>

Published online: 19 January 2023

 Check for updates

Kara W. Chew , Carlee Moser , Eric S. Daar, David A. Wohl , Jonathan Z. Li , Robert W. Coombs , Justin Ritz , Mark Giganti, Arzhang Cyrus Javan, Yijia Li, Manish C. Choudhary, Rinki Deo, Carlos Malvestutto, Paul Klekotka, Karen Price, Ajay Nirula, William Fischer, Veenu Bala, Ruy M. Ribeiro , Alan S. Perelson , Courtney V. Fletcher , Joseph J. Eron , Judith S. Currier , ACTIV-2/A5401 Study Team, Michael D. Hughes & Davey M. Smith 

The original version of this article contained an error in the Abstract, which incorrectly omitted from the end the following: ‘Trial Registration: ClinicalTrials.gov Identifier: NCT04518410’. This has been corrected in both the PDF and HTML versions of the Article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023